Related Experiment Videos
Cyclosporin pharmacokinetics in the elderly
1Department of Clinical Pharmacology, Novartis Pharma AG, Basel, Switzerland. john.kovarik@pharma.novartis.com
Drugs & Aging
|September 30, 1999
Summary
Cyclosporin pharmacokinetics do not significantly differ in the elderly. However, older adults may face increased risks of drug interactions due to polypharmacy, requiring careful monitoring.
Area of Science:
- Pharmacology
- Geriatrics
- Immunology
Background:
- Cyclosporin is an essential immunosuppressant for organ transplantation and autoimmune diseases.
- The elderly population is a growing demographic for these indications.
- Age-related changes in drug metabolism and transport pathways could theoretically alter cyclosporin disposition.
Purpose of the Study:
- To investigate the pharmacokinetic profile of cyclosporin in elderly patients.
- To determine if age necessitates dosage adjustments for cyclosporin therapy.
- To assess the impact of aging on cyclosporin disposition and variability.
Main Methods:
- Review of existing pharmacokinetic studies on cyclosporin in elderly individuals.
- Analysis of single-dose studies comparing elderly and young adults.
- Evaluation of population pharmacokinetic data in organ transplant recipients.
Main Results:
- Single-dose studies show no significant pharmacokinetic differences between healthy elderly and young adults.
- Cyclosporin disposition in elderly rheumatoid arthritis patients is similar to younger individuals.
- Population pharmacokinetic analysis did not identify age as a significant covariate.
Conclusions:
- Available data suggest no age-related pharmacokinetic differences requiring dose adjustments in the elderly.
- Elderly patients are more susceptible to drug-drug interactions due to polypharmacy.
- Heightened awareness of potential drug interactions is crucial when prescribing cyclosporin to elderly patients.